ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,713.64
      0.00%
      US Tech 100
      19,325.20
      -0.05%
      Dow Jones
      42,025.19
      0.00%
      Brent Oil
      73.975
      -0.46%
      Bitcoin
      62,937.45
      -0.02%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Adial Pharmaceuticals Inc (ADIL) Quote

      Adial Pharmaceuticals Inc

      Adial Pharmaceuticals Inc (ADIL)

      NASDAQ
      1.05
      -0.03
      (-2.78%)
      Closed September 19 4:00PM
      Delayed by 15 minutes
      1.05
      0.00
      ( 0.00% )
      Pre Market: 8:30AM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      1.05
      Bid
      1.05
      Ask
      1.10
      Volume
      -
      0.00 Day's Range 0.00
      0.765 52 Week Range 4.30
      Market Cap
      6.724M
      Previous Close
      1.05
      Open
      -
      Last Trade
      Last Trade Time
      -
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      3,061,525
      Shares Outstanding
      6,403,381
      Dividend Yield
      -
      PE Ratio
      -1.31
      Earnings Per Share (EPS)
      -0.8
      Revenue
      -
      Net Profit
      -5.12M

      About Adial Pharmaceuticals Inc

      Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.adialpharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Adial Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADIL. The last closing price for Adial Pharmaceuticals was $1.05. Over the last year, Adial Pharmaceuticals shares have traded in a share price range of $ 0.765 to $ 4.30.

      Adial Pharmaceuticals currently has 6,403,381 shares outstanding. The market capitalization of Adial Pharmaceuticals is $6.72 million. Adial Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.31.

      Ask ADVFN Intelligence (AI)

      ADIL Latest News

      More News

      Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

      GLEN ALLEN, Va., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      September 19 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

      GLEN ALLEN, Va., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      September 04 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

      GLEN ALLEN, Va., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      August 14 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 13 2024
      Edgar (US Regulatory)

      Adial Pharmaceuticals Signs Agreement with Boudicca Dx to Advance Regulatory Strategy for Companion Diagnostic Genetic Test for AD04

      GLEN ALLEN, Va., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      August 13 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

      Patient dosing has concluded for the second and last cohort of the pharmacokinetics study of AD04 Topline results expected during the fourth quarter GLEN ALLEN, Va., Aug. 07, 2024 (GLOBE...

      August 07 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

      GLEN ALLEN, Va., July 31, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      July 31 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

      GLEN ALLEN, Va., July 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      July 23 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

      GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing...

      June 20 2024
      GlobeNewswire Inc.

      Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

      Study intended to optimize design elements needed for the upcoming US Pivotal Phase 3 studiesand support ongoing partnership discussions Topline results expected in early Q4 2024 GLEN ALLEN, Va...

      June 05 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.05-4.545454545451.11.121.051286651.07611909CS
      40.05225.231509320510.99781.120.951316911.04400365CS
      12-0.09-7.894736842111.1430.930615251.29012719CS
      26-0.73-41.01123595511.783.10.927220701.83389139CS
      52-1.47-58.33333333332.524.30.76523658111.98884007CS
      156-100.7-98.9680589681101.751270.76511876007.72454551CS
      260-35.95-97.1621621622371270.765101653624.10140464CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      XPONExpion360 Inc
      $ 0.127
      (118.21%)
      		181.7M
      LFLYLeafly Holdings Inc
      $ 3.24
      (81.01%)
      		4.64M
      BNZIBanzai International Inc
      $ 4.9399
      (71.52%)
      		6.54M
      VERBVerb Technology Company Inc
      $ 0.0848
      (52.52%)
      		13.44M
      TNONTenon Medical Inc
      $ 6.71
      (33.40%)
      		4.11M
      CRBPCorbus Pharmaceuticals Holdings Inc
      $ 24.05
      (-53.48%)
      		212.26k
      KOPNKopin Corporation
      $ 0.6796
      (-29.51%)
      		860.34k
      BFIBurgerFi International Inc
      $ 0.1118
      (-24.51%)
      		1.11M
      NVECNVE Corporation
      $ 60.00
      (-24.23%)
      		57
      TOMZTOMI Environmental Solutions Inc
      $ 0.585
      (-23.03%)
      		1.06k
      XPONExpion360 Inc
      $ 0.1263
      (117.01%)
      		181.75M
      SVMHSRIVARU Holding Ltd
      $ 0.151
      (21.77%)
      		42.17M
      AKTSAkoustis Technologies Inc
      $ 0.0682
      (0.15%)
      		16.54M
      VERBVerb Technology Company Inc
      $ 0.0868
      (56.12%)
      		13.7M
      RRRichtech Robotics Inc
      $ 0.9934
      (7.69%)
      		9.46M

      ADIL Discussion

      View Posts
      Awl416 Awl416 2 months ago
      Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044
      👍️0
      FROZENFLAME FROZENFLAME 2 months ago
      Looks like green very soon !
      👍️0
      FROZENFLAME FROZENFLAME 2 months ago
      Interesting !
      👍️0
      glenn1919 glenn1919 2 months ago
      ADIL............................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
      👍️0
      tw0122 tw0122 2 months ago
      Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

      Source: GlobeNewswire Inc.

      Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced the progression to the second cohort in the pharmacokinetics study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients (defined as < 10 drinks/drinking day), following the successful completion of the first cohort. Topline results from both cohorts are expected to be announced during the fourth quarter of 2024.
      Cary Claiborne, President and Chief Executive Officer of Adial commented, “We are pleased with the progress of our pharmacokinetics study of AD04. The successful completion of the first cohort allows us to advance to the second cohort as planned, staying on track with our projected timeline. The results from both cohorts will offer invaluable insights that are critical for the design of our upcoming Phase 3 Clinical Trial. We anticipate engaging with the FDA following receipt of the topline data from this study and seek their feedback on the overall design of our Phase 3 program.”

      The pharmacokinetics study was initiated in June 2024 and is expected to be completed during the fourth quarter of 2024. The single-center open-label relative bioavailability and dose proportionality study will enroll up to 30 healthy adult volunteers and compare the pharmacokinetic profile of AD04 when administered as an oral dose of 0.33 mg with or without food against a reference standard product. This study will provide valuable information on the pharmacokinetic properties of AD04.

      👍️0
      Monksdream Monksdream 2 months ago
      ADIL under $2
      👍️0
      Monksdream Monksdream 2 months ago
      ADIL under $2
      👍️0
      glenn1919 glenn1919 4 months ago
      ADIL....................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 5 months ago
      ADIL under $1
      👍️0
      Awl416 Awl416 5 months ago
      What leaked?
      👍️0
      44Skell 44Skell 5 months ago
      Where to now ADIL?
      👍️0
      Klinsmann Klinsmann 5 months ago
      Sorry to say, I was deadly wrong on this one... But I´m holding and adding.
      👍️0
      Klinsmann Klinsmann 5 months ago
      Holding up very well. And flagging for the next uptick. Jep, it‘s supposed to happen…
      👍️ 1
      44Skell 44Skell 5 months ago
      Isn’t this stock suppose to be ticking up
      👍️0
      Invest-in-America Invest-in-America 5 months ago
      ADIL: Boy, am I eatin' 'CROW' on this one, or what!!! (Likely Close today at $5.00, just to humiliate me even more!!!)


      "Heck, I trash a stock, & then it soars to the MOON!!! I HATE when this happens!!! NO RESPECT, at all!!!"
      🤣 1
      glenn1919 glenn1919 5 months ago
      ADIL...............................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Invest-in-America Invest-in-America 5 months ago
      ADIL: This is what one gets behind 'investing' in a mere Ultra-Pre-Human-Trials, Petri Dish, Test Tude, Theoretical Journal Paper, and otherwise, 'THE-GREAT-ALCOHOL-ADDICTION-MAYBE-COULD-BE-MIGHT-BE-YEARS-FROM-NOW-CURE-OF-THE-WEEK', fluffy, Wall Street 'news' routine.
      👍️0
      TheFinalCD TheFinalCD 5 months ago
      tHANKS adiL 1.82
      👍️0
      Klinsmann Klinsmann 5 months ago
      Congrats- chart looks primed for more…
      👍️0
      TheFinalCD TheFinalCD 5 months ago
      filled 1.97 on that dip
      👍️0
      TheFinalCD TheFinalCD 5 months ago
      $ADIL 2.54 LET MORE GO, WHAT A GREAT STOCK TO TRADE

      https://finviz.com/quote.ashx?t=ADIL&ty=c&ta=1&p=d

      $adil lots of trade oppshttps://t.co/0eN6zQg6CR— THE FINAL COUNTDOWN (@READY_2_PROFIT) April 10, 2024
      👍️0
      TheFinalCD TheFinalCD 5 months ago
      CONGRAT$
      👍️0
      TheFinalCD TheFinalCD 5 months ago
      nhod https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174209695
      👍️0
      Klinsmann Klinsmann 5 months ago
      Overdue- go time again!
      👍️0
      Awl416 Awl416 5 months ago
      What leaked?
      👍️0
      Klinsmann Klinsmann 6 months ago
      Added more shares - rumors about a big pharma deal hopefully get published soon…
      👍️0
      Monksdream Monksdream 6 months ago
      ADIL 10Q due 3/18
      👍️0
      maent maent 7 months ago
      I'm totally out. It was a nice bounce. We will see if it drops back into a buy zone. GL all.
      👍️0
      Bill_ENG Bill_ENG 7 months ago
      Except for the failed Phase III and then the company not doing anything except for a reverse split in two years.

      They need to run more trials it will take 3 to 4 years to prove effectiveness and a higher probability it will fail those trials.

      Having a patent on something that doesn't work is not worth much.

      Jmho
      👍️0
      glenn1919 glenn1919 7 months ago
      ADIL................................................https://stockcharts.com/h-sc/ui?s=ADIL&p=W&b=5&g=0&id=p86431144783
      👍️0
      Lottoplay Lottoplay 7 months ago
      “AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity” my projected selling price just went higher! I didn’t know it treated gambling and obesity in addition to alcoholism and opioid addiction! BOOM!!!
      👍️0
      Lottoplay Lottoplay 7 months ago
      BOOM! Posted yesterday! “ADIL this company has the potential to be worth #BILLIONS and at the same time help alcoholics and opioid addicts! Making money and helping humanity, who doesn’t want to be a part of that!”
      👍️0
      maent maent 7 months ago
      I'm now looking for a nice bounce over $5
      👍️0
      BurgerKing82 BurgerKing82 7 months ago
      This one looks good
      👍️0
      Lottoplay Lottoplay 7 months ago
      $ADIL this company has the potential to be worth #BILLIONS and at the same time help alcoholics and opioid addicts! Making money and helping humanity, who doesn’t want to be a part of that! 🚀
      👍️0
      Awl416 Awl416 7 months ago
      Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office
      👍️0
      maent maent 7 months ago
      I'm looking for a nice bounce back over $1
      👍️0
      Monksdream Monksdream 7 months ago
      ADIL new 52 week low
      👍️0
      maent maent 7 months ago
      My stop loss hit at 1.04
      👍️0
      Monksdream Monksdream 7 months ago
      ADIL new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      ADIL new 52 week low
      👍️0
      maent maent 7 months ago
      Looks like a nice entry point here.
      👍️0
      eb0783 eb0783 7 months ago
      Cat got your tongue?
      👍️0
      Monksdream Monksdream 7 months ago
      ADIL new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      ADIL new 52=week low
      👍️0
      Monksdream Monksdream 7 months ago
      ADIL new 52 week low
      🌈 1 🍆 1 👎️ 1 🩳 1
      Monksdream Monksdream 8 months ago
      ADIL new 52 week high
      👍️0
      Monksdream Monksdream 8 months ago
      ADIL new 52 week low
      👍️0
      Muhbruh Muhbruh 9 months ago
      $ADIL another small bio getting attention now pic.twitter.com/oCNyRr81Tj— STOCKS Gambino (@StocksGambino) December 29, 2023
      👍️0
      Zorro Zorro 9 months ago
      Volume picking up but also dropping in price. Looks like there is historic support in the 1.80 area.
      👍️0

      Your Recent History

      NASDAQ
      ADIL
      Adial Pharmaceuticals
      Delayed Upgrade Clock